AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22027731 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (DEB)
Number of subjects: 0
Study 22027731 — intervention group
Group type: COMPARATOR
Intervention: Regular balloon
Number of subjects: 0
Study 18315426 — intervention group
Group type: EXPERIMENTAL
Intervention: SDD-40 (40 mg doxycycline, once daily)
Number of subjects: 266
Study 18315426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 17060062 — intervention group
Group type: EXPERIMENTAL
Intervention: olmesartan 20 mg
Number of subjects: 18
Study 17060062 — intervention group
Group type: EXPERIMENTAL
Intervention: olmesartan 20 mg plus glibenclamide 3.5 mg
Number of subjects: 18
Study 17060062 — intervention group
Group type: COMPARATOR
Intervention: glibenclamide 3.5 mg
Number of subjects: 18
Study 15228823 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis for VTE (group-A)
Number of subjects: 249
Study 15228823 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis for VTE (group-B)
Number of subjects: 249
Study 11426360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone (50 microg/kg during 10 minutes followed by 0.5 microg/kg/min)
Number of subjects: 120
Study 11426360 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dobutamine (10 to 20 microg/kg/min)
Number of subjects: 120
Study 11426360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone
Number of subjects: 120
Study 11426360 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dobutamine
Number of subjects: 120
Study 9402176 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF concentration in aqueous fluid of the anterior chamber of the eye
Number of subjects: 15
Study 9402176 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF concentration in serum
Number of subjects: 15
Study 9402176 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF concentration in urine
Number of subjects: 15
Study 9402176 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF concentration in fluid from renal cysts
Number of subjects: 15
Study 9402176 — intervention group
Group type: COMPARATOR
Intervention: Concentrations of bFGF, IL-8, and ET-1 in serum and urine
Number of subjects: 15
Study 8435895 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 24-hour infusion of 2 IU GH
Number of subjects: 12
Study 8435895 — intervention group
Group type: EXPERIMENTAL
Intervention: Two intravenous boluses of 2 IU GH
Number of subjects: 12
Study 8435895 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight intravenous boluses of 2 IU GH every 3 hours
Number of subjects: 12
Study 8435895 — intervention group
Group type: EXPERIMENTAL
Intervention: Single subcutaneous injection of 0.2 U/kg GH
Number of subjects: 12
Study 8435895 — intervention group
Group type: COMPARATOR
Intervention: Untreated normal controls
Number of subjects: 12
Study 2441642 — intervention group
Group type: EXPERIMENTAL
Intervention: nicergoline
Number of subjects: 20
Study 2441642 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 31917129 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent family-based prevention program
Number of subjects: 255
Study 31917129 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 255
Study 28864265 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid group (continuous motion parameter feedback)
Number of subjects: 36
Study 28864265 — intervention group
Group type: COMPARATOR
Intervention: Regular box group (no motion parameter feedback)
Number of subjects: 36
Study 27146827 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal gel
Number of subjects: 2750
Study 27146827 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tablet
Number of subjects: 2750
Study 24996416 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 0
Study 24996416 — intervention group
Group type: COMPARATOR
Intervention: Better health state
Number of subjects: 0
Study 23252208 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% bupivacaine with adrenaline
Number of subjects: 47
Study 23252208 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NSS
Number of subjects: 47
Study 19651405 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management programme
Number of subjects: 0
Study 19651405 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18450928 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognition and symptoms
Number of subjects: 1386
Study 18450928 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive syndrome scale of PANSS
Number of subjects: 1386
Study 18450928 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognition and symptom measures during treatment
Number of subjects: 1386
Study 16184439 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic carotid endarterectomy (CEA) within 1 week before major surgery
Number of subjects: 79
Study 16184439 — intervention group
Group type: COMPARATOR
Intervention: Deferred carotid endarterectomy (CEA) between 30 days and 6 months after major surgery
Number of subjects: 79
Study 12637464 — intervention group
Group type: EXPERIMENTAL
Intervention: Arzoxifene 20 mg
Number of subjects: 112
Study 12637464 — intervention group
Group type: EXPERIMENTAL
Intervention: Arzoxifene 50 mg
Number of subjects: 112
Study 11131781 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 microg)
Number of subjects: 237
Study 11131781 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 237
Study 11131781 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of oral misoprostol (400 microg)
Number of subjects: 237
Study 11131781 — intervention group
Group type: EXPERIMENTAL
Intervention: Both routes of administration
Number of subjects: 237
Study 8931083 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 12
Study 8931083 — intervention group
Group type: EXPERIMENTAL
Intervention: Assist/control (A/C)
Number of subjects: 12
Study 8931083 — intervention group
Group type: COMPARATOR
Intervention: Conventional intermittent mandatory ventilation (IMV)
Number of subjects: 12
Study 1306633 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour nicotine delivery
Number of subjects: 158
Study 1306633 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine delivery during wakeful hours only
Number of subjects: 158
Study 1306633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 1306633 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches
Number of subjects: 158
Study 3511821 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE‐CytaBOM
Number of subjects: 69
Study 3511821 — intervention group
Group type: COMPARATOR
Intervention: ProMACE‐MOPP
Number of subjects: 69
Study 31713442 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention over 6 months
Number of subjects: 247
Study 31713442 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep quality
Number of subjects: 247
Study 30513970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic drink (KD 4:1)
Number of subjects: 0
Study 30513970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic drink (KD 1.7:1)
Number of subjects: 0
Study 30513970 — intervention group
Group type: COMPARATOR
Intervention: Balanced nutrition drink (BD)
Number of subjects: 0
Study 27756567 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2.5mA, 20 sessions of 30min duration over 4 weeks)
Number of subjects: 120
Study 27756567 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (2.5mA, 20 sessions of 30min duration over 4 weeks)
Number of subjects: 120
Study 23635729 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system
Number of subjects: 129
Study 23635729 — intervention group
Group type: COMPARATOR
Intervention: Control group (no levonorgestrel-releasing intrauterine system)
Number of subjects: 129
Study 21364487 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Heating (PaH)
Number of subjects: 8
Study 21364487 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-Induced Hyperthermia (ExH)
Number of subjects: 8
Study 21364487 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study 19843783 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal 10 mg lidocaine 2% plus 10 microg fentanyl (Group I)
Number of subjects: 52
Study 19843783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 3 mg levobupivacaine 0.5% plus 10 microg fentanyl (Group II)
Number of subjects: 52
Study 17199533 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibroblast injections
Number of subjects: 20
Study 17199533 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 20
Study 15262418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin incorporated into gel and suspension formulations
Number of subjects: 0
Study 15262418 — intervention group
Group type: COMPARATOR
Intervention: Chitosan gel alone
Number of subjects: 0
Study 15262418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin suspension
Number of subjects: 0
Study 15262418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin formulations
Number of subjects: 0
Study 11816552 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 0
Study 11816552 — intervention group
Group type: COMPARATOR
Intervention: Racemate omeprazole
Number of subjects: 0
Study 9609412 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral ciprofloxacin 750 mg b.i.d.
Number of subjects: 5
Study 9609412 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ciprofloxacin 400 mg b.i.d.
Number of subjects: 5
Study 7810782 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-rigid ankle orthosis (Sport-Stirrup)
Number of subjects: 504
Study 7810782 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-braced) with previous sprains
Number of subjects: 504
Study 7810782 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-braced) without previous sprains
Number of subjects: 504
Study 3185292 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS‐oestradiol 50 micrograms
Number of subjects: 13
Study 3185292 — intervention group
Group type: COMPARATOR
Intervention: Conjugated oestrogens 1.25 mg
Number of subjects: 13
Study 3185292 — intervention group
Group type: COMPARATOR
Intervention: Oestradiol valerate 2 mg
Number of subjects: 13
Study 31230222 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of donepezil hydrochloride and choline supplement
Number of subjects: 60
Study 31230222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28351897 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive low glucose management (PLGM ON)
Number of subjects: 100
Study 28351897 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented insulin pump with PLGM OFF
Number of subjects: 100
Study 28351897 — intervention group
Group type: EXPERIMENTAL
Intervention: PLGM ON
Number of subjects: 100
Study 24802530 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with adapalene 0.1% gel and ketoconazole 2% cream once daily for 2 weeks
Number of subjects: 0
Study 24802530 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole 2% cream twice daily for 2 weeks (monotherapy group)
Number of subjects: 0
Study 23331844 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg testosterone undecanoate (n = 10)
Number of subjects: 21
Study 23331844 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 21
Study 21463970 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulative Techniques (SMT)
Number of subjects: 90
Study 21463970 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 90
Study 21463970 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 90
Study 18398586 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation for prophylaxis of heterotopic ossification (HO)
Number of subjects: 0
Study 21241828 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intensive management of CVD risk factors for one year by a nurse practitioner/community health worker (NP/CHW) team
Number of subjects: 525
Study 21241828 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 525
Study 16042028 — intervention group
Group type: EXPERIMENTAL
Intervention: Referential communication task
Number of subjects: 0
Study 16042028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cookie Theft Picture Description test
Number of subjects: 0
Study 16042028 — intervention group
Group type: EXPERIMENTAL
Intervention: CADL test
Number of subjects: 0
Study 12477584 — intervention group
Group type: EXPERIMENTAL
Intervention: rapacuronium 0.25 mg x kg(‐1) i.v. (Group 1)
Number of subjects: 69
Study 12477584 — intervention group
Group type: EXPERIMENTAL
Intervention: rapacuronium 0.5 mg x kg(‐1) i.v. (Group 2)
Number of subjects: 69
Study 12477584 — intervention group
Group type: EXPERIMENTAL
Intervention: rapacuronium 0.75 mg x kg(‐1) i.v. (Group 3)
Number of subjects: 69
Study 9804031 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of mind tasks (including an emotion prediction task involving either a nice or a nasty surprise)
Number of subjects: 40
Study 9804031 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion understanding stories (requiring affective perspective-taking skills and situational understanding)
Number of subjects: 40
Study 9804031 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple executive function tasks (adapted for preschoolers, tapping inhibitory control, attentional set-shifting, and working memory)
Number of subjects: 40
Study 9804031 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function performance
Number of subjects: 40
Study 7637161 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.2 mg‐1.0 mg)
Number of subjects: 31
Study 7637161 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 5 mg
Number of subjects: 31
Study 7637161 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 31
Study 7637161 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 31
Study 7637161 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 31
Study 2693557 — intervention group
Group type: EXPERIMENTAL
Intervention: Human amniotic fluid (HAF) as a complete medium
Number of subjects: 0
Study 2693557 — intervention group
Group type: COMPARATOR
Intervention: T6 + 10% HS medium
Number of subjects: 0
Study 657108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional Bacillus Calmette-Guerin (BCG)
Number of subjects: 18
Study 657108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional dinitrochlorobenzene (DNCB)
Number of subjects: 18
Study 29507124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive audit and feedback with daily-updated team-based data dashboard and weekly in-person review of performance data ('STAT rounds')
Number of subjects: 40
Study 29507124 — intervention group
Group type: COMPARATOR
Intervention: Usual audit and feedback with ongoing twice-monthly emails with graphical depictions of team performance
Number of subjects: 40
Study 29507124 — intervention group
Group type: EXPERIMENTAL
Intervention: Washout period after cessation of STAT rounds
Number of subjects: 40
Study 27449404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg)
Number of subjects: 105
Study 27449404 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (4 mg)
Number of subjects: 105
Study 27449404 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 ml)
Number of subjects: 105
Study 25337035 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC transfusion at a Hb threshold of 8.9 g/dL (liberal group)
Number of subjects: 66
Study 25337035 — intervention group
Group type: COMPARATOR
Intervention: RBC transfusion at a Hb threshold of 7.3 g/dL (restrictive group)
Number of subjects: 66
Study 23507372 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal HIV infection
Number of subjects: 1502
Study 23507372 — intervention group
Group type: EXPERIMENTAL
Intervention: Young maternal age, low maternal education, low birth weight, early weaning, higher number of episodes of malaria during infancy
Number of subjects: 1502
Study 23507372 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of living children in the family
Number of subjects: 1502
Study 23507372 — intervention group
Group type: COMPARATOR
Intervention: Stunting
Number of subjects: 1502
Study 23507372 — intervention group
Group type: COMPARATOR
Intervention: Underweight
Number of subjects: 1502
Study 23507372 — intervention group
Group type: COMPARATOR
Intervention: Wasting
Number of subjects: 1502
Study 20018364 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 microg non-adjuvant split-virion vaccine
Number of subjects: 12691
Study 20018364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12691
Study 18278987 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone augmentation
Number of subjects: 45
Study 18278987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 16025970 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) combined with Ginsenosides (GS)
Number of subjects: 80
Study 16025970 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (Dex)
Number of subjects: 80
Study 16025970 — intervention group
Group type: COMPARATOR
Intervention: Ginsenosides (GS)
Number of subjects: 80
Study 16025970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12946740 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 5 mg twice daily
Number of subjects: 66
Study 12946740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 12946740 — intervention group
Group type: COMPARATOR
Intervention: Control/Standard therapy
Number of subjects: 66
Study 11062287 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral severe ICA stenosis (70% to 99%)
Number of subjects: 386
Study 11062287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesser degrees of contralateral ICA stenosis (less than 70%)
Number of subjects: 386
Study 11062287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesser degrees of contralateral ICA stenosis (11 to 21 cm/s)
Number of subjects: 386
Study 8912126 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TBS)
Number of subjects: 30
Study 8912126 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate
Number of subjects: 30
Study 8912126 — intervention group
Group type: COMPARATOR
Intervention: Aluminium hydroxide
Number of subjects: 30
Study 1714018 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms)
Number of subjects: 8
Study 7128190 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine oral rinse
Number of subjects: 52
Study 7128190 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral rinse
Number of subjects: 52
Study 31442785 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week home-based brisk walking program
Number of subjects: 159
Study 31442785 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 159
Study 29940255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol suppression at encoding
Number of subjects: 0
Study 29940255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cortisol suppression)
Number of subjects: 0
Study 29940255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol levels
Number of subjects: 0
Study 23981567 — intervention group
Group type: COMPARATOR
Intervention: Aquatic treadmill (ATM) running
Number of subjects: 12
Study 23145517 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based simulation activities
Number of subjects: 58
Study 23145517 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-based simulation activities
Number of subjects: 58
Study 23145517 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-English first-language students
Number of subjects: 58
Study 20235087 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral carbohydrate loading; 61.0% compliance in audit group vs 96% in trial group; P < 0.001
Number of subjects: 195
Study 20235087 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse incision; 25.0% in audit group vs 39% in trial group; P = 0.037
Number of subjects: 195
Study 20235087 — intervention group
Group type: EXPERIMENTAL
Intervention: Early fluid and diet reintroduction; 73.0% in audit group vs 99% in trial group; P < 0.001
Number of subjects: 195
Study 20235087 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-opiate postoperative oral analgesia; 70.0% in audit group vs 99% in trial group; P < 0.001
Number of subjects: 195
Study 20235087 — intervention group
Group type: COMPARATOR
Intervention: Length of hospital stay; median 7 days (audit group) vs 6 days (trial group); no significant difference
Number of subjects: 195
Study 20235087 — intervention group
Group type: COMPARATOR
Intervention: Septic morbidity; not available
Number of subjects: 195
Study 20235087 — intervention group
Group type: COMPARATOR
Intervention: 30-day mortality rates; not available
Number of subjects: 195
Study 18617752 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior vitrectomy (group A, 19 eyes)
Number of subjects: 40
Study 18617752 — intervention group
Group type: COMPARATOR
Intervention: Posterior optic capture without vitrectomy (group B, 21 eyes)
Number of subjects: 40
Study 16091636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 94
Study 16091636 — intervention group
Group type: COMPARATOR
Intervention: Control (no lisinopril)
Number of subjects: 94
Study 12519102 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) at a final dose of 900-2100 mg for 14 days, followed by 7 days without OXC, then 14 days back on OXC.
Number of subjects: 12
Study 12519102 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) during the on-periods.
Number of subjects: 12
Study 11979208 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based intervention protocols for nurse-led continence service
Number of subjects: 0
Study 11979208 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led continence service
Number of subjects: 0